Sanofi SA (SNY)
48.89
-0.47
(-0.95%)
USD |
NASDAQ |
Apr 26, 10:21
Sanofi Enterprise Value: 131.80B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 131.80B |
| April 24, 2024 | 124.93B |
| April 23, 2024 | 127.63B |
| April 22, 2024 | 126.28B |
| April 19, 2024 | 124.16B |
| April 18, 2024 | 121.88B |
| April 17, 2024 | 123.68B |
| April 16, 2024 | 122.91B |
| April 15, 2024 | 124.01B |
| April 12, 2024 | 123.23B |
| April 11, 2024 | 124.90B |
| April 10, 2024 | 126.23B |
| April 09, 2024 | 127.23B |
| April 08, 2024 | 126.28B |
| April 05, 2024 | 126.53B |
| April 04, 2024 | 127.90B |
| April 03, 2024 | 128.30B |
| April 02, 2024 | 127.65B |
| April 01, 2024 | 129.12B |
| March 28, 2024 | 129.90B |
| March 27, 2024 | 132.25B |
| March 26, 2024 | 132.77B |
| March 25, 2024 | 132.00B |
| March 22, 2024 | 128.58B |
| March 21, 2024 | 127.73B |
| Date | Value |
|---|---|
| March 20, 2024 | 128.98B |
| March 19, 2024 | 127.10B |
| March 18, 2024 | 127.98B |
| March 15, 2024 | 129.12B |
| March 14, 2024 | 128.63B |
| March 13, 2024 | 129.00B |
| March 12, 2024 | 129.55B |
| March 11, 2024 | 129.27B |
| March 08, 2024 | 129.03B |
| March 07, 2024 | 128.55B |
| March 06, 2024 | 127.60B |
| March 05, 2024 | 127.15B |
| March 04, 2024 | 126.28B |
| March 01, 2024 | 126.63B |
| February 29, 2024 | 128.03B |
| February 28, 2024 | 128.40B |
| February 27, 2024 | 128.93B |
| February 26, 2024 | 128.90B |
| February 23, 2024 | 130.32B |
| February 22, 2024 | 127.90B |
| February 21, 2024 | 128.20B |
| February 20, 2024 | 125.53B |
| February 16, 2024 | 123.86B |
| February 15, 2024 | 124.38B |
| February 14, 2024 | 122.91B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
106.37B
Minimum
Sep 27 2022
154.26B
Maximum
Apr 11 2022
134.86B
Average
135.89B
Median
Nov 01 2019
Enterprise Value Benchmarks
| AstraZeneca PLC | 254.28B |
| GSK PLC | 97.93B |
| Novo Nordisk A/S | 559.86B |
| Regeneron Pharmaceuticals Inc | 88.90B |
| Inhibrx Inc | 1.545B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -597.68M |
| Revenue (Quarterly) | 13.14B |
| Total Expenses (Quarterly) | 11.04B |
| EPS Diluted (Quarterly) | -0.2369 |
| Gross Profit Margin (Quarterly) | 66.82% |
| Profit Margin (Quarterly) | -4.55% |
| Earnings Yield | 4.79% |
| Operating Earnings Yield | 9.19% |
| Normalized Earnings Yield | 6.497 |